BioSmart바이오스마트
038460 · KOSDAQ · ₩038460 · 바이오스마트
₩2,460▲ ₩40 (1.65%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩483B | ₩484B | ₩456B | ₩392B | ₩189B |
| Cost of sales | ₩398B | ₩402B | ₩377B | ₩315B | ₩121B |
| Gross profit | ₩85B | ₩82B | ₩79B | ₩77B | ₩68B |
| Operating income | ₩23B | ₩20B | ₩10B | ₩10B | ₩8B |
| Net income | ₩9B | ₩1.1B | ₩16B | −₩1.2B | ₩634M |
| Net income to shareholders | ₩9B | ₩127M | ₩18B | ₩721M | ₩1.4B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩310B | ₩263B | ₩260B | ₩237B | ₩226B |
| Current assets | ₩154B | ₩134B | ₩135B | ₩130B | ₩119B |
| Cash and equivalents | ₩30B | ₩11B | ₩21B | ₩20B | ₩14B |
| Total liabilities | ₩122B | ₩106B | ₩138B | ₩145B | ₩134B |
| Current liabilities | ₩90B | ₩79B | ₩120B | ₩131B | ₩91B |
| Borrowings | ₩72B | ₩48B | ₩74B | ₩79B | ₩68B |
| Total equity | ₩188B | ₩156B | ₩122B | ₩92B | ₩92B |
| Shareholders' equity | ₩144B | ₩129B | ₩112B | ₩97B | ₩99B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩24B | ₩3.7B | ₩1.2B | ₩6.3B | ₩1.2B |
| Capital spending | ₩33B | ₩6.9B | ₩3.1B | ₩4.4B | ₩4.8B |
| Free cash flow | −₩9.2B | −₩3.2B | −₩1.9B | ₩1.9B | −₩3.6B |
| Dividends paid | — | — | — | ₩360M | — |
Consolidated where available. Amounts in won.
Also known as: BioSmart / 바이오스마트 / 038460 / KRX:038460
Source: KRX statistical information